SG3 Management’s Boston Scientific BSX Stock Holding History

SG3 Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000	Closed	-$43K	–	1052
2021 Q3	$43K	Sell	1,000 -1,000	-50%	-$44.2K	﹤0.01%	916
2021 Q2	$86K	Buy	+2,000	New	+$84.1K	﹤0.01%	908
2019 Q3	–	Sell	-25,000	Closed	-$1.07M	–	343
2019 Q2	$1.07M	Buy	+25,000	New	+$962K	0.12%	151

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

SG3 Management's BSX Position: Q4 2021 in Review

SG3 Management sold out of Boston Scientific (BSX) in Q4 2021, closing a stake of 1,000 shares — an estimated $43K sold.

SG3 Management first reported a position in BSX in Q2 2019 and held it in 3 quarters. The position peaked at $1.07M in Q2 2019. 888 funds tracked by Wall St. Rank hold BSX as of Q4 2021.

SG3 Management reported no remaining Boston Scientific position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 1,000 Boston Scientific shares in Q4 2021, an estimated $43K.
SG3 Management first reported a position in Boston Scientific in Q2 2019 and held it in 3 quarters.
SG3 Management's Boston Scientific position peaked at $1.07M in Q2 2019.
888 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.